KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression.

Ali, Amjad; Zhang, P; Liangfang, Y; Wenshe, S; Wang, H; Lin, X; Dai, Y; Feng, XH; Moses, Robb E.; Wang, D; Li, X; Xiao, J

doi:10.1038/cddis.2015.48

Article (Scientific journals)

KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression.

Ali, Amjad; Zhang, P; Liangfang, Y et al.

2015 • In Cell Death and Disease

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/182187

DOI
10.1038/cddis.2015.48

PubMed
25766320

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

cddis201548a.pdf

Author preprint (2.22 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

smad3; klf17; metastasis

Abstract :

[en] Inhibition of tumor suppressive signaling is linked to cancer progression, metastasis and epithelial-mesenchymal transition (EMT). Transforming growth factor-β1 (TGF-β)/Smad signaling plays an important role in tumor suppression. Kruppel-like-factor 17 (KLF17) is a negative regulator of metastasis and EMT. However, underlying mechanisms leading to tumor suppressive and anti-metastatic function of KLF17 still remains unknown. Here, we show that KLF17 plays an integral role in potentiating TGF-β/Smad signaling via Smad3-dependent pathway to suppress tumor progression. Intriguingly, TGF-β/Smad3 signaling induces KLF17 expression, generating a positive feedback loop. TGF-β/Smad3-KLF17 loop is critical for anti-metastasis and tumor inhibition in cancer cells. Mechanistically, silencing KLF17 reduced Smad3-DNA complex formation on Smad binding element (SBE) and affects the expression of TGF-β/Smad target genes. Moreover, KLF17 alters Smad3 binding pattern on chromatin. KLF17 regulates TGF-β target genes that are Smad3-dependent. Smad3 and KLF17 physically interact with each other via KLF17 responsive elements/SBE region. Intriguingly, TGF-β stimulates the recruitment of KLF17 on chromatin to subsets of metastasis-associated genes. Functionally, depletion of KLF17 enhanced tumorigenic features in cancer cells. KLF17 is critical for full cytostatic function of TGF-β/Smad signaling. Clinically, KLF17 expression significantly decreases during advance HCC. KLF17 shows positive correlation with Smad3 levels in cancer samples. Our data shows that enhance KLF17 activity has important therapeutic implications for targeted-therapies aimed at TGF-β/Smad3 pathway. These findings define novel mechanism by which TGF-β/Smad-KLF17 pathway mutually affect each other during cancer metastasis, provide a new model of regulation of TGF-β/Smad signaling by KLF17 and defines new insights into anti-metastatic function of KLF17.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Ali, Amjad ; Université de Liège > Département de pharmacie > Chimie médicale

Zhang, P

Liangfang, Y

Wenshe, S

Wang, H

Lin, X

Dai, Y

Feng, XH

Moses, Robb E.

Wang, D

Li, X

Xiao, J

Language :

English

Title :

KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression.

Publication date :

12 March 2015

Journal title :

Cell Death and Disease

eISSN :

2041-4889

Publisher :

Nature Pub.lishing Group, London, United Kingdom

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 June 2015

Statistics

Number of views

29 (3 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM et al. Estimates of worldwide burden of cancer in 2008. Int J Cancer 2008; 127: 2893-2917.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
Sun Z, Meng C, Wang S, Zhou N, Guan M, Bai C et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer 2014; 27: 616.
Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 2005; 85: 551-556.
Black AR, Black JD, Azizkhan-Clifford J. Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-160.
Moore DL, Blackmore MG, Hu Y, Kaestner KH, Bixby JL, Lemmon VP et al. KLF family members regulate intrinsic axon regeneration ability. Science 2009; 326: 298-301.
Marie PT, Yizeng Y, Jonathan PK. Krüppel-like factors in cancer. Nat Rev Cancer 2013; 13: 701-713.
James JB. Krüppel-like factors: three fingers in many pies. J Biol Chem 2001; 276: 34355-34358.
Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009; 11: 1297-1304.
Iwanicki MP, Brugge JS. Transcriptional regulation of metastatic [Id] entity by KLF17. Genome Biol 2009; 10: 244.
Dong P, Kaneuchi M, Xiong Y, Cao L, Cai M, Liu X et al. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis 2013; 35: 760-768.
Liu FY, Deng YL, Li Y, Zeng D, Zhou ZZ, Tian DA et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol 2013; 30: 425.
Sun Z, Han Q, Zhou N, Wang S, Lu S, Bai C et al. MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Mol Oncol 2013; 7: 884-894.
Massagui J. TGF-β in cancer. Cell 2008; 134: 215-230.
Derynck R, Zhang Y E. Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 2003; 425: 577-584.
Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005; 23: 2078-2093.
Shi Y, Massagui J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
Siegel PM, Massagui J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807-821.
Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-176.
Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine and Growth Factor Rev 2006; 17: 41-58.
Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. PNAS 2003; 100: 8621-8623.
Meulmeester E, Dijke PT. The dynamic roles of TGF-β in cancer. J Pathol 2011; 223: 205-218.
Inman GJ. Switching TGFβ from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011; 21: 93-99.
Huang T, David L, Mendoza V, Yang Y, Villarreal M, De K et al. TGF-β signalling is mediated by two autonomously functioning TβRI: TβRII pairs. EMBO J 2011; 30: 1263-1276.
Massagui J. A very private TGF-β receptor embrace. Mol Cell 2008; 29: 149-150.
Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-2810.
Heldin CH, Moustakas A. Role of Smads in TGFβ signaling. Cell Tissue Res 2012; 347: 21-26.
Feng XH, Derynck R. Specificity and versatility in TGF-β signaling through smads. Ann Rev Cell Dev Biol 2005; 21: 659-693.
Ali A, Wang Z, Fu J, Ji L, Liu J, Li L et al. Differential regulation of the REGgammaproteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat Commun 2013; 4: 2667.
Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S et al. Links between tumor suppressors: p53 is required for TGF-β gene responses by cooperating with Smads. Cell 2003; 113: 301-314.
Dupont S, Zacchigna L, Adorno M, Soligo S, Volpin D, Piccolo S et al. Convergence of p53 and TGF-β signaling networks. Cancer Lett 2004; 213: 129-138.
Wei J, Li Z, Chen W, Ma C, Zhan F, Wu W et al. AEG-1 participates in TGF-beta1-induced EMT through p38 MAPK activation. Cell Biol Int 2013; 37: 1016-1021.
Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L et al. TGF-β Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep 2013; 5: 1228-1242.
Kang Y, Chen CR, Massagué J. A self-enabling TGF-beta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003; 11: 915-926.
Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15 (Ink4B) transcription in response to TGF-beta. EMBO J 2000; 19: 5178-5193.
Hong HY, Jeon WK, Kim SJ, Kim BC. 14-3-3 σ is a new target up-regulated by transforming growth factor-β1 through a Smad3-dependent mechanism. Biochem Biophys Res Commun 2013; 432: 193-197.
Spender LC, Carter MJ, O'Brien DI, Clark LJ, Yu J, Michalak EM et al. Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas. J Biol Chem 2013; 288: 5198-5209.
Li H, Xu D, Li J, Berndt MC, Liu JP. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J Biol Chem 2006; 281: 25588-25600.
Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 2004; 24: 2546-2559.
Fink SP, Mikkola D, Willson JK, Markowitz S. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003; 22: 1317-1323.
Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ et al. The Smad4 protein and prognosiss of pancreatic ductal adnocarcinoma. Clin Cancer Res 2001; 7: 4115-4121.
Losi L, Bouzourene H, Benhattar J. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep 2007; 17: 1095-1099.
White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D et al. Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest 2013; 123: 4390-4404.
Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011; 71: 998-1008.
Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 2010; 138: 969-980.
Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278: 21113-21123.
Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2.